



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Director’s Shareholding**

**London: Thursday, 8 August 2013:** Chi-Med received notification on 8 August 2013 that Mr Christopher Nash, Independent Non-executive Director of Chi-Med, purchased 8,506 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) at a price of GBP5.84 each on 7 August 2013.

Following this purchase, Mr Nash is beneficially interested in 26,506 Shares, representing approximately 0.05% of the current issued share capital of Chi-Med.

**Ends**

**Enquiries**

<b>Chi-Med</b> Christian Hogg, CEO	Telephone: +852 2121 8200
<b>Panmure Gordon (UK) Limited</b> Richard Gray Andrew Potts Grishma Patel	Telephone: +44 20 7886 2500
<b>Citigate Dewe Rogerson</b> Anthony Carlisle David Dible	Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919

**About Chi-Med**

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.